Ahead of its intended transition to the Nasdaq, Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) is offering shareholders the chance to engage with an independent financial planner and understand what the imminent ASX delisting means for their investment.
IHL shareholders with a holding in their superannuation account will have the opportunity to sit down with MLS Financial and discuss the best investment strategy moving forward.
Incannex says engaging MLS means shareholders will receive qualified, independent and strictly confidential advice that weighs all factors contributing to the holder’s financial position.
Throughout the process, MLS will analyse the shareholder's current position and provide support and recommendations on the next best steps for the holder, in addition to outlining how Incannex is transitioning its share listing from the ASX to the Nasdaq.
Any and all shareholders seeking clarity or advice on their IHL holding within a superannuation structure are encouraged to email admin@incannex.com.au.
“Seamless transition”
Incannex Healthcare CEO Joel Latham said the board’s unanimous decision to redomicile on the Nasdaq was taken to unlock maximum value for shareholders.
“At the time that Incannex proposed the change from ASX to Nasdaq, the board committed that it would do all that it could to ensure a seamless transition of their investment from Australia to the United States,” he explained.
“Incannex shareholders who feel they would benefit from this service will receive independent advice from a financial group that is fully understanding of the change Incannex is making, and will also learn how best to advise each shareholder independently in light of this change.
“On that basis, we encourage those shareholders to seek the confidential and independent superannuation advice that the company offers.”
Speaking to plans to redomicile in early July, Incannex said a Nasdaw listing would glean the following benefits:
- Improved access to large pools of lower-cost equity capital over the long term;
- increased alignment with prominent pharmaceutical companies;
- a simplified corporate structure for any future potential merger or acquisition transactions; and
- enhanced access to FDA resources.